文献速递间质性肺疾病

特发性肺纤维化患者家庭监测的随机对照试验

Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

该多中心随机对照试验纳入90例新治疗的特发性肺纤维化患者,比较标准治疗联合24周家庭监测方案与单独标准治疗。结果显示家庭监测未显著改善K-BILD总评分,但心理领域评分有改善趋势,且药物调整更频繁、患者满意度高。

要点

  • 家庭监测未显著改善IPF患者24周K-BILD总评分。
  • 家庭监测组药物调整次数更多,患者满意度高。
  • 家庭肺功能与医院肺功能随时间高度相关。

核心结论

  • 综合家庭监测方案未改善IPF患者整体健康相关生活质量,但倾向于改善心理幸福感。
  • 家庭监测受患者高度认可,并支持个体化药物调整。

研究设计与样本

  • 多中心随机对照试验,纳入90例新治疗的特发性肺纤维化患者。
  • 46例分配至家庭监测组,44例分配至标准治疗组,干预24周。

主要发现

  • 24周时K-BILD总分家庭监测组增加2.70分(SD=9.5),标准治疗组增加0.03分(SD=10.4),组间差异2.67分(95%CI -1.85至7.17;P=0.24)。
  • 心理领域评分家庭监测组增加5.12分(SD=15.8),标准治疗组下降0.48分(SD=13.3),组间差异5.6分(95%CI -1.13至12.3;P=0.10)。
  • 家庭监测组每例患者药物调整1次,标准治疗组0.3次(95%CI 0.2至1.3;P=0.027)。
  • 患者对家庭监测方案满意度高,家庭肺功能与医院肺功能随时间高度相关。

临床怎么用

  • 家庭监测可作为IPF患者个体化药物调整的辅助工具。
  • 家庭肺功能与医院肺功能高度相关,支持远程监测可行性。
  • 家庭监测可能改善心理幸福感,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Idiopathic pulmonary fibrosis (IPF) is a deadly disease with increasingly impaired health-related quality of life (HRQOL). eHealth technologies facilitate collection of physiological outcomes and patient-reported outcomes at home, but randomized controlled trials (RCTs) on the effects of eHealth are scarce.Objectives: To investigate whether a home monitoring program improves HRQOL and medication use for patients with IPF.Methods: We performed a multicenter RCT in newly treated patients with IPF. Patients were randomly assigned to standard care or a home monitoring program on top of standard care for 24 weeks. The home monitoring program included home spirometry, reporting of symptoms and side effects, patient-reported outcomes, information, a medication coach, and eConsultations. The primary endpoint was between-group difference in change in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score at 24 weeks.Measurements and Main Results: A total of 90 patients were randomized (46 assigned to the home monitoring group and 44 to the standard care group). After 24 weeks, no statistically significant difference was found in K-BILD total score, with a 2.70-point increase in the home monitoring group (SD = 9.5) and a 0.03-point increase in the standard care group (SD = 10.4); between-group difference was 2.67 points (95% confidence interval [CI], -1.85 to 7.17; P = 0.24). Between-group difference in psychological domain score was 5.6 points (95% CI, -1.13 to 12.3; P = 0.10), with an increase of 5.12 points in the home monitoring group (SD = 15.8) and a decline of 0.48 points in the standard care group (SD = 13.3). In the home monitoring group, medication was more often adjusted (1 vs. 0.3 adjustments per patient; 95% CI, 0.2 to 1.3; P = 0.027). Patient satisfaction with the home monitoring program was high. Home-based spirometry was highly correlated with hospital-based spirometry over time.Conclusions: The results of this first-ever eHealth RCT in IPF showed that a comprehensive home monitoring program did not improve overall HRQOL measured with K-BILD but tended to improve psychological well-being. Home monitoring was greatly appreciated by patients and allowed for individually tailored medication adjustments.Clinical trial registered with www.clinicaltrials.gov (NCT03420235).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Moor CC, Mostard RLM, Grutters JC, et al. Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2020. PMID: 32325005. doi:10.1164/rccm.202002-0328OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。